Ravn
Senior Member (Voting Rights)
Full title:
Intranasal Administration of ACIS KEPTIDETM Prevents SARS-CoV2-Induced Acute
Toxicity in K18-hACE2 Humanized Mouse Model of COVID-19: A Mechanistic Insight for
the Prophylactic Role of KEPTIDETM in COVID-19
Gunnar Gottschalk, James F Keating, Kris Kesler, Konstance Knox and Avik Roy
https://doi.org/10.1101/2020.11.13.378257
pre-print, in a few mice
Intranasal Administration of ACIS KEPTIDETM Prevents SARS-CoV2-Induced Acute
Toxicity in K18-hACE2 Humanized Mouse Model of COVID-19: A Mechanistic Insight for
the Prophylactic Role of KEPTIDETM in COVID-19
Gunnar Gottschalk, James F Keating, Kris Kesler, Konstance Knox and Avik Roy
https://doi.org/10.1101/2020.11.13.378257
pre-print, in a few mice
Abstract:
Previously, we have demonstrated that ACIS KEPTIDETM, a chemically modified peptide, selectively binds to ACE-2 receptor and prevents the entry of SARS-CoV2 virions in vitro in primate kidney Cells. However, it is not known if ACIS KEPTIDETM attenuates the entry of SARS-CoV2 virus in vivo in lung and kidney tissues, protects health, and prevent death once applied through intranasal route.
In our current manuscript, we demonstrated that the intranasal administration of SARS-CoV2 (1*106) strongly induced the expression of ACE-2, promoted the entry of virions into the lung and kidney cells, caused acute histopathological toxicities, and mortality (28%). Interestingly, thirty-minutes of pre-treatment with 50 μg/Kg Body weight ACIS normalized the expression of ACE-2 via receptor internalization, strongly mitigated that viral entry, and prevented mortality suggesting its prospect as a prophylactic therapy in the treatment of COVID-19. On the contrary, the peptide backbone of ACIS was unable to normalize the expression of ACE-2, failed to improve the health vital signs and histopathological abnormalities.
In summary, our results suggest that ACIS is a potential vaccine-alternative, prophylactic agent that prevents entry of SARS-CoV2 in vivo, significantly improves respiratory health and also dramatically prevents acute mortality in K18-hACE2 humanized mice.